You just read:

Debiopharm International SA Announces Dosing of First Patient in a Combination Trial of Debio 1143 and Avelumab in Patients with Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC)

News provided by

Debiopharm International SA

06 Nov, 2017, 08:00 GMT